US admits multiple molecular formulations effective in cardiovascular diseases

thehealthsite | May 30, 2019

US admits multiple molecular formulations effective in cardiovascular diseases
Recently, the chairman of the mega exhibition of the Pharmaceutical Export Promotion Council of India said that the US and other advanced countries which initially opposed benefits of multiple molecular formulations for cardiovascular and diabetic treatment, have now started realizing and accepting them The Indian pharmaceutical industry has been successful in engineering multiple molecular formulations for cardiovascular and diabetic treatment, which the US and other advanced countries had initially opposed.“When the Indian companies came out with multiple molecule formulations, the US and other advanced countries had vehemently opposed it but now they have started realizing and accepting the benefits of it,” Vijay Shah, the chairman of the mega exhibition of the Pharmaceutical Export Promotion Council of India.The seventh edition of this flagship exhibition of the Council, which showcases the best of Indian pharma capability to global buyers, will be held at the Mahatma Gandhi exhibition ground in the state capital Gandhinagar from June 10 to June 12. The union commerce ministry is sponsoring the event, providing for the travel and accommodation expenses of all the 738 buyers from across 130 countries, while the Gujarat government has provided the exhibition venue at subsidized rates.“Gujarat is the hub of pharmaceutical industry in India, with a share of about 30 per cent of the total exports. Recognizing this, we are holding this event for the first time in the state. This year, our focus is on the Medium and Small Enterprises (SMEs),” Shah said. The export promotion council’s Executive Director Raghuveen Kini said, “We will help the SMEs in resolving issues and hindrances faced by them in exporting their products abroad and participation in global pharma events.”“We are also sending delegations to Australia, New Zealand, China, Latin American countries like Mexico and Peru as well as CIS countries, including Russia, Belarus, Uzbekistan, Kazakhstan and Armenia,” Kini added. The Indian pharma industry is hoping for 15 per cent growth in exports over the previous years, Kini said. India is the third largest pharma exporter in the world and its export business is valued at over 19 billion US dollars.

Spotlight

Stability testing of a drug substance or a finished product is a vital part of the data package submitted in support of new drug applications or marketing authorisations. The principle ethos of stability testing is to provide evidence to a regulatory body that the quality of the product or raw material does not vary with time or under the influence of a range of other factors including temperature, humidity and light.

Spotlight

Stability testing of a drug substance or a finished product is a vital part of the data package submitted in support of new drug applications or marketing authorisations. The principle ethos of stability testing is to provide evidence to a regulatory body that the quality of the product or raw material does not vary with time or under the influence of a range of other factors including temperature, humidity and light.

Related News

BUSINESS INSIGHTS

Quotient Sciences Acquires Arcinova

Quotient Sciences, Arcinova | February 09, 2021

Quotient Sciences, the drug development and manufacturing accelerator, reported that it has procured Arcinova, the U.K.- based multiservice contract development and manufacturing organization (CDMO). With more than 40 years of involvement and 160 representatives, Arcinova gives drug substance, drug item and bioanalysis administrations to more than 200 pharma and biotech clients around the world. The obtaining expands Quotient's administration portfolio and will empower the incorporation of drug substance, drug item and clinical testing abilities all under one organization broadening the year drug development course of events investment funds previously conveyed by Quotient's flagship platform Translational Pharmaceutics®. By slicing through storehouses and incorporating a scope of capacities, rethought development projects can be additionally improved and quickened, reliable with Quotient's conviction that particles need to become fixes, quick. “I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “I’d also like to take this moment to thank our private equity partner, Permira, for supporting our ambitious growth plans.” Professor Ian Shott, CBE, co-founder and executive chairman of Arcinova, said, “Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers.” As part of the deal, Arcinova’s minority equity partner, BGF, will exit the business, having backed its growth since 2018. Mark Bryant, BGF, said, “It has been a privilege to support the expansion of Arcinova’s world-leading CDMO facility at such a critical part of its growth journey. We wish the team all the best as it moves to the next stage with Quotient Sciences.” RBC Capital Markets went about as selective monetary counselor to Quotient Sciences. PwC gave monetary and charge due industriousness administrations and Latham and Watkins gave legal counsel. BGF got legal counsel from Weightmans. KPMG filled in as corporate money guide for Arcinova, and Womble Bond Dickinson gave legal counsel. About Quotient Sciences Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. About Arcinova Arcinova is a multiservice contract development and manufacturing organization (CDMO) that serves pharmaceutical and biotechnology companies across the globe in developing their life changing medicines. The company, with decades of experience, combines agility with flexibility to provide an innovative approach to the development and manufacture of pharmaceutical products. Arcinova’s ambition is to save our clients valuable time, enabling them to rapidly bring life-changing medicines to market.

Read More

U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine

Biohaven Pharmaceutical Holding Company Ltd. | October 14, 2020

Biohaven Pharmaceutical Holding Company Ltd. today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) goal date for completion of the FDA review of the preventive sNDA is set for 2Q2021. Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "Patients with migraine deserve the simplicity of managing their disease with a single medication that alleviates acute episodes and also works to prevent future attacks. Our goal with the NURTEC ODT development program has been to offer a fast acting, quick-dissolve oral tablet with "dual-acting" properties --acute and preventive-- to treat migraine across its full spectrum. We believe that the ease of use associated with a single oral medication will benefit people with migraine so that they can take back their days, and also provides the health care system with a cost-effective approach as opposed to paying for two separate drugs for acute and preventive treatment."

Read More

AstraZeneca spinoff Viela Bio scored its first FDA nod. Can it face down heavyweight rivals?

Fiercepharma | June 16, 2020

Two years after launching, AstraZeneca spinoff Viela Bio has its first FDA approval in Uplinza following Friday's nod to treat certain patients with neuromyelitis optica spectrum disorder. Analysts expect that the medicine, which won approval to treat patients who are anti-AQP4 antibody positive, can generate $586 million by 2026, according to Evaluate. But the competitive landscape could pose a challenge for the biotech's first launch. Doctors could prescribe Roche’s Rituxan or its biosimilars off label before trying Uplinza, Evaluate Vantage reports, or payers could require them to try the cheaper options first. Uplinza is a B cell depleter like Rituxan, so if those older options don’t work, docs might go another route and try Alexion’s Soliris rather than move on to Uplinza, Vantage said.

Read More